Endotoxin removal: How far from the evidence? the EUPHAS 2 project

Contributions to Nephrology

Volumn 167, Issue , 2010, Pages 119-125

  Martin, Erica L ^a   Cruz, Dinna N ^b,c   Monti, Gianpaola ^d   Casella, Gianpaolo ^d   Vesconi, Sergio ^d   Ranieri, V Marco ^a   Ronco, Claudio ^b,c   Antonelli, Massimo ^e  

^a UNIVERSITY OF TURIN   (Italy)

^b SAN BORTOLO HOSPITAL   (Italy)

^c International Renal Research Institute (IRRIV)   (Spain)

^d OSPEDALE NIGUARDA CA GRANDA   (Italy)

^e CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; ENDOTOXIN; LIPOPOLYSACCHARIDE; POLYMYXIN B;

ARTICLE; BINDING SITE; BLOOD; CRITICAL ILLNESS; GRAM NEGATIVE INFECTION; HEMOPERFUSION; HUMAN; INJURY; INTENSIVE CARE UNIT; ISOLATION AND PURIFICATION; ITALY; JAPAN; MEDICAL SOCIETY; METABOLISM; METHODOLOGY; RANDOMIZED CONTROLLED TRIAL; SEPTIC SHOCK; UNITED STATES;

AMERICAN MEDICAL ASSOCIATION; ANTI-BACTERIAL AGENTS; BINDING SITES; CRITICAL ILLNESS; ENDOTOXINS; GRAM-NEGATIVE BACTERIAL INFECTIONS; HEMOPERFUSION; HUMANS; INTENSIVE CARE UNITS; ITALY; JAPAN; LIPOPOLYSACCHARIDES; POLYMYXIN B; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SHOCK, SEPTIC; UNITED STATES; WOUNDS AND INJURIES;

EID: 77954567135     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000315926     Document Type: Article

References (9)

1. Kellum JA: A targeted extracorporeal therapy for endotoxemia: the time has come. Crit Care 2007;11:137.
2. Klein DJ, Derzko A, Seeley A, et al: Marker or mediator̈ Changes in endotoxin activity as a predictor of adverse outcomes in critical illness. Crit Care 2005;9(Suppl 1):161.
3. Opal SM, Scannon PJ, Vincent JL, et al: Relationship between plasma levels of lipopolysaccharide (LPS) and LPS-binding protein in patients with severe sepsis and septic shock. J Infect Dis 1999;180:1584-1589.
4. Marshall JC, Foster D, Vincent JL, et al: Diagnostic and prognostic implications of endotoxemia in critical illness: results of the MEDIC study. J Infect Dis 2004;190:527-534.
5. Manocha S, Feinstein D, Kumar A: Novel therapies for sepsis: antiendotoxin therapies. Expert Opin Investig Drugs 2002,11:1795-1812.
6. Cruz DN, Perazella MA, Bellomo R, et al: Effectiveness of polymyxin B-immobilized fiber column in sepsis: a systematic review. Crit Care 2007;11:R47.
7. Cruz DN, Antonelli M, Fumagalli R, et al: Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA 2009;301: 2445-2452.
8. Kellum JA, Uchino S: International differences in the treatment of sepsis: are they justified? JAMA 2009;301:2496-2497.
9. Valenza F, Fagnani L, Coppola S, et al: Prevalence of endotoxemia after surgery and its association with ICU length of stay. Crit Care 2009;13:R102.